-
-
-
-
-
-
-
Lipocine Provides Regulatory Update for TLANDO™
-
-
-
-
-
-
-
Lipocine (LPCN) Announces Treatment Potential of LPCN 1144 Demonstrated in Pre-Clinical NASH and Hepatic Fibrosis Model
-
-
-
-
-
-
-
Lipocine (LPCN) Announces US Court of Appeals for Federal Circuit Affirms Decision of USPTO
-
-
-
-
-
-
-
Lipocine Announces Second Quarter 2019 Financial and Operational Results
-
-
-
-
-
-
-
Pre-Open Movers 01/11: (SECO) (NBEV) (MGI) Higher; (LPCN) (HMNY) (APPN) Lower (more...)
-
-
-
-
-
-
-
Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017
-
-
-
-
-
-
-
Lipocine (LPCN) Resubmits NDA for Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

